Skip to main content

Table 1 Clinical variables in patients with high and low expression of PAR2

From: Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma

VariablePAR2 expressionP value
Low expressionHigh expression
 Sample size63139 
 Age, years  0.074
  > 5025 (39.7%)74 (53.2%) 
  ≤5038 (60.3%)65 (46.8%) 
Gender  0.187
 Male57 (90.5%)116 (83.5%) 
 Female6 (9.5%)23 (16.5%) 
AFP, ng/mL  0.067
  < 2018 (28.6%)24 (17.3%) 
  ≥ 2045 (71.4%)115 (82.7%) 
Cirrhosis  0.889
 Yes53 (84.1%)118 (84.9%) 
 No10 (15.9%)21 (15.1%) 
Tumor size, cm  0.154
  < 523 (36.5%)37 (26.6%) 
  ≥ 540 (63.5%)102 (73.4%) 
Differentiation  < 0.001
 Well-moderate22 (34.9%)12 (8.6%) 
 Poor-undifferentiated41 (65.1%)127 (91.4%) 
TNM stage  0.015
 I–II42 (66.7%)67 (48.2%) 
 III–IV21 (33.3%)72 (51.8%) 
Vascular invasion  0.290
 Yes8 (12.7%)26 (18.7%) 
 No55 (87.3%)113 (81.3%) 
  1. Abbreviations: PAR2 proteinase activated receptor 2, AFP alpha-fetoprotein